ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Pharmacology & Therapeutics
Volume 104, Issue 2, November 2004, Pages 117-135
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (479 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pharmthera.2004.07.008    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2004 Elsevier Inc. All rights reserved.

Associate editor: N.W. Quick

Anandamide transport

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Matthew J. McFarland and Eric L. BarkerCorresponding Author Contact Information, E-mail The Corresponding Author

Department of Medical Chemistry and Molecular Pharmacology, Purdue University, 575 Stadium Mall Drive, West Lafayetta, IN 47907-2091, USA


Available online 30 September 2004.

Abstract

N-Arachidonylethanolamine (anandamide) is an endogenous agonist of the cannabinoid CB1 and CB2 receptors and displays many of the same receptor-mediated physiological effects as Δ9-tetrahydrocannabinol (Δ9-THC), the active component of marijuana. As with any neurotransmitter, there must be tight control of anandamide receptor-mediated signaling and a means of rapid removal of the molecule from the system. Thus, the process by which anandamide is transported into the cell for metabolism has been a topic of much interest and has been implicated as a potential drug target in the treatment of several disease states that are reported to have an association with the endocannabinoid system. In this review, we will discuss the current models proposed for the mechanism of anandamide transport, the progress that has been made in the development of compounds that specifically inhibit anandamide transport, the observed effects of anandamide transport inhibition in vivo, and finally, potential therapeutic applications of compounds that inhibit anandamide transport.

Keywords: Cannabinoid; Anandamide; Transporter; Δ9-Tetrahydorcannabinol; Marijuana; Amidohydrolyase

Abbreviations: Δ9-THC, Δ9-tetrahydrocannabinol; 2-AG, sn2-arachidonyl glycerol; AEA, anandamide; CREAE, chronic relapsing experimental allergic encephalomyelitis; CNS, central nervous system; DAG, diacylglycerol; FAAH, fatty acid amide hydrolase; FAAH−/− mice, FAAH knockout mice; MAFP, methylarachidonylfluorophosphonate; GI, gastrointestinal; NAPE, N-arachidonylphosphatidylethanolamine; PLD, phospholipase D; PMSF, phenylmethylsulfonyl fluoride; SARI, selective AEA reuptake inhibitors; TRPV1, transient receptor potential vanilloid type 1 receptor; virodhamine, O-arachidonoyl-ethanolamine

Article Outline

1. Introduction
1.1. Cannabinoid receptors
1.2. Anandamide as an endogenous cannabinoid
1.3. Biosynthesis of anandamide
1.4. Termination of anandamide signaling
2. Anandamide transport
2.1. Anandamide transport by a carrier-mediated process
2.2. Facilitated diffusion mediated by fatty acid amide hydrolase
2.3. Sequestration of anandamide by cells
2.4. Anandamide uptake by endocytic processes
2.5. Inhibition of anandamide transport
3. In vivo studies of anandamide transport and metabolism
3.1. Fatty acid amide hydrolase knockout mice
3.2. Anandamide reuptake inhibitors in vivo
4. Potential therapeutic implications of anandamide transport inhibition
4.1. Analgesia
4.2. Anxiety
4.3. Spasticity
4.4. Neuropsychiatric disorders
4.5. Other potential therapeutic applications
5. Discussion
Acknowledgements
References




Corresponding Author Contact InformationCorresponding author. Tel.: 765 494 9940; fax: 765 494 1414.

Pharmacology & Therapeutics
Volume 104, Issue 2, November 2004, Pages 117-135
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.